Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wedbush in a research report issued to clients and investors on Friday. They presently have a $33.00 price target on the stock. Wedbush’s price target points to a potential upside of 95.38% from the company’s current price.

A number of other research analysts have also issued reports on VRNA. Stifel Nicolaus initiated coverage on Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. They set a “buy” rating and a $22.00 price target for the company. SunTrust Banks, Inc. initiated coverage on Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. They set a “buy” rating and a $26.00 price target for the company. Jefferies Group LLC reiterated a “buy” rating and set a $26.00 price target on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, May 22nd. Finally, Zacks Investment Research upgraded Verona Pharma PLC American Depositary Share from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Tuesday, July 25th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $24.20.

Shares of Verona Pharma PLC American Depositary Share (VRNA) opened at 16.89 on Friday. The firm has a 50-day moving average price of $12.49 and a 200-day moving average price of $13.60. Verona Pharma PLC American Depositary Share has a 12-month low of $11.03 and a 12-month high of $50.88. The firm’s market cap is $186.87 million.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last announced its quarterly earnings results on Tuesday, August 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.28) by $0.09. On average, equities research analysts expect that Verona Pharma PLC American Depositary Share will post ($2.23) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Verona Pharma PLC American Depositary Share (VRNA) Rating Reiterated by Wedbush” was originally published by Daily Political and is owned by of Daily Political. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.dailypolitical.com/2017/09/10/verona-pharma-plc-american-depositary-share-vrna-rating-reiterated-by-wedbush.html.

Several institutional investors have recently made changes to their positions in VRNA. FIL Ltd purchased a new stake in shares of Verona Pharma PLC American Depositary Share during the second quarter valued at $873,000. Tekla Capital Management LLC purchased a new stake in shares of Verona Pharma PLC American Depositary Share during the second quarter valued at $3,211,000. Finally, Vivo Capital LLC purchased a new stake in shares of Verona Pharma PLC American Depositary Share during the second quarter valued at $8,208,000. Institutional investors and hedge funds own 30.16% of the company’s stock.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.

Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.